Adverse Effect of Other Antipsychotics and NeurolepticsNCT02604056
Pragmatic Cluster Trial for Nursing Home Antipsychotic Prescribing
A study testing Audit + Feedback and Audit + Feedback + Educational Outreach in people with Adverse Effect of Other Antipsychotics and Neuroleptics, run by Women's College Hospital.
Trial summary
Two arm, pragmatic, cluster-randomized trial, with nursing homes allocated to the full, active intervention (featuring educational outreach offered to each prescriber and team members in the home) or standard quality improvement supports (including online audit and feedback reports for each prescriber in the home). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Adverse Effect of Other Antipsychotics and Neuroleptics
- What is being tested?
- Audit + Feedback and Audit + Feedback + Educational Outreach
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Sep 2015to Apr 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Nursing homes within pre-determined regions of Ontario that expressed an interest in the full intervention (the regions, or hubs, contain a wide variety of nursing home types within a reasonable travel distance [i.e., <100 km])
- Nursing homes within the hubs in which the medical and administrative leads agree to and support the project
Who cannot join
- Nursing homes with a previous or ongoing involvement in externally supported quality improvement initiatives focusing on antipsychotic medications
- Nursing homes without any prescribers caring for at least 10 residents routinely
- Nursing homes with fewer than 30 residents
About this study
Official title: Ontario Appropriate Prescribing Demonstration Project: Pragmatic, Cluster-Randomized Clinical Trial to Reduce Antipsychotic Medication Prescribing in Long-Term Care Homes
Two arm, pragmatic, cluster-randomized trial, with nursing homes allocated to the full, active intervention (featuring educational outreach offered to each prescriber and team members in the home) or standard quality improvement supports (including online audit and feedback reports for each prescriber in the home). The 'standard' quality improvement supports represent 'usual care' as these are to be launched province-wide; a concurrent control arm with no exposure to a quality improvement intervention is not feasible.
Read the detailed description
The Ministry of Health and Long-Term Care and Ontario Medical Association have initiated a project aiming to improve appropriateness of prescribing in long-term care facilities (aka nursing homes) through integrated educational supports for nursing home prescribers, inter-professional care teams, as well as residents and family members. The first focus of the project is appropriate prescribing of antipsychotic medications. Working with Health Quality Ontario, the policy makers have determined that all prescribers will have the opportunity to review practice reports detailing their prescribing performance for this class of medication (aka audit and feedback).
The primary question of this pragmatic, cluster-randomized trial is: What is the effect of adding educational outreach compared to the 'usual' quality improvement supports (i.e. audit and feedback) on prescribing of antipsychotic medications in long-term care?
Secondary questions include the following:
- What is the effect of the intervention on acute care utilization (e.g., emergency room) rates? ii. What is the effect of the intervention on incidence of patient clinical outcomes and/or adverse effects associated with antipsychotic medications (e.g., falls, aggressive behaviours)? iii. What is the effect of the interventions on medications that might be used as alternatives to antipsychotic medications (e.g., benzodiazepines)? iv. What is the cost-benefit, focusing on prescribing outcomes?
Process evaluation questions include the following:
- How and why do the interventions work as observed?
- Was the intervention implemented as desired in nursing homes?
- What were the contextual factors associated with implementation?
- Do the interventions affect precursors of behaviour (e.g., motivation, capability)?
- Being tested
- Audit + Feedback, Audit + Feedback + Educational Outreach
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Audit + FeedbackBehavioural
Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
Audit + Feedback + Educational OutreachBehavioural
The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: "an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia." The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home.
| Study group | Role | What they receive |
|---|---|---|
| Audit + Feedback | Active comparator | 'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home) Receives: Behavioral: Audit + Feedback |
| Audit + Feedback + Educational Outreach | Experimental | 'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home) Receives: Behavioral: Audit + Feedback; Behavioral: Audit + Feedback + Educational Outreach |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antipsychotic dispensing
Number of days with antipsychotic prescriptions in the last week (count, range 0 - 7)
Measured: 6 months post-intervention
Secondary outcomes (12)
Antipsychotic prescribing
Any antipsychotic prescription during the past month (dichotomous)
Measured: 3 and 6 months post-intervention
Mean Antipsychotic dose
Dose equivalent of antipsychotic dispensed in the past month (continuous)
Measured: 3 and 6 months post-intervention
Benzodiazepine (or sedative) prescribing
Any prescription during the past month (dichotomous)
Measured: 3 and 6 months post-intervention
Anti-depressant prescribing
Any prescription during the past month (dichotomous)
Measured: 3 and 6 months post-intervention
Acetaminophen prescribing
Any prescription during the past month (dichotomous)
Measured: 3 and 6 months post-intervention
Difficulty in performing activities
Activities of Daily Living long form scale (continuous variable, range 0-28)
Measured: 3 and 6 months post-intervention
Aggressive behaviour scale
Extent of aggressive behaviour (continuous variable, range 0-12)
Measured: 3 and 6 months post-intervention
Pain
Pain scale (continuous variable, range 0-3)
Measured: 3 and 6 months post-intervention
Depression
Depression rating scale (continuous variable, range 0-14)
Measured: 3 and 6 months post-intervention
Falls
Number of falls in the past month (count)
Measured: 3 and 6 months post-intervention
Emergency Room visits
Number of ER visits during the previous 3 months (count)
Measured: 3 months post-intervention
Hospitalizations
Number of hospital visits visit during the previous 3 months (count)
Measured: 3 months post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2015 (estimated)
- Study startSep 2015
- Primary completionApr 2017
- Study completionApr 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Adverse Effect of Other Antipsychotics and NeurolepticsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Women's College Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Ontario Ministry of Health and Long Term Care, Ontario Medical Association, Health Quality Ontario, Centre for Effective Practice
- Responsible party
- Sponsor
- Investigators
- Noah Ivers, Principal investigator, Family Doctor and Research Scientist
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02604056
- Sponsor's protocol ID
- MOHLTCAPDP
- Status last verified
- Mar 2018
- First submitted
- 5 Nov 2015
- Last updated
- 23 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Tadrous M, Fung K, Desveaux L, Gomes T, Taljaard M, Grimshaw JM, Bell CM, Ivers NM. Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2020 May 1;3(5):e205724. doi: 10.1001/jamanetworkopen.2020.5724.
PubMed 32453383Desveaux L, Saragosa M, Rogers J, Bevan L, Loshak H, Moser A, Feldman S, Regier L, Jeffs L, Ivers NM. Improving the appropriateness of antipsychotic prescribing in nursing homes: a mixed-methods process evaluation of an academic detailing intervention. Implement Sci. 2017 May 26;12(1):71. doi: 10.1186/s13012-017-0602-z.
PubMed 28549480Desveaux L, Gomes T, Tadrous M, Jeffs L, Taljaard M, Rogers J, Bell CM, Ivers NM. Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. Implement Sci. 2016 Mar 29;11:45. doi: 10.1186/s13012-016-0410-x.
PubMed 27026584
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ontario Appropriate Prescribing Demonstration Project: Pragmatic, Cluster-Randomized Clinical Trial to Reduce Antipsychotic Medication Prescribing in Long-Term Care Homes
- ClinicalTrials.gov ID
- NCT02604056
- Acronym / sponsor ID
- MOHLTCAPDP
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Women's College HospitalUniversity, hospital or other
- Collaborators
- Ontario Ministry of Health and Long Term Care, Ontario Medical Association, Health Quality Ontario, Centre for Effective Practice
- Study start
- Sep 2015 (actual)
- Primary completion
- Apr 2017 (actual)
- Study completion
- Apr 2017 (actual)
- First posted
- 13 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Two arm, pragmatic, cluster-randomized trial, with nursing homes allocated to the full, active intervention (featuring educational outreach offered to each prescriber and team members in the home) or standard quality improvement supports (including online audit and feedback reports for each prescriber in the home). The 'standard' quality improvement supports represent 'usual care' as these are to be launched province-wide; a concurrent control arm with no exposure to a quality improvement intervention is not feasible.
Detailed description
The Ministry of Health and Long-Term Care and Ontario Medical Association have initiated a project aiming to improve appropriateness of prescribing in long-term care facilities (aka nursing homes) through integrated educational supports for nursing home prescribers, inter-professional care teams, as well as residents and family members. The first focus of the project is appropriate prescribing of antipsychotic medications. Working with Health Quality Ontario, the policy makers have determined that all prescribers will have the opportunity to review practice reports detailing their prescribing performance for this class of medication (aka audit and feedback).
The primary question of this pragmatic, cluster-randomized trial is: What is the effect of adding educational outreach compared to the 'usual' quality improvement supports (i.e. audit and feedback) on prescribing of antipsychotic medications in long-term care?
Secondary questions include the following:
- What is the effect of the intervention on acute care utilization (e.g., emergency room) rates? ii. What is the effect of the intervention on incidence of patient clinical outcomes and/or adverse effects associated with antipsychotic medications (e.g., falls, aggressive behaviours)? iii. What is the effect of the interventions on medications that might be used as alternatives to antipsychotic medications (e.g., benzodiazepines)? iv. What is the cost-benefit, focusing on prescribing outcomes?
Process evaluation questions include the following:
- How and why do the interventions work as observed?
- Was the intervention implemented as desired in nursing homes?
- What were the contextual factors associated with implementation?
- Do the interventions affect precursors of behaviour (e.g., motivation, capability)?
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Audit + Feedback | Active comparator | Behavioral: Audit + Feedback'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home) |
| Audit + Feedback + Educational Outreach | Experimental | Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Nursing homes within pre-determined regions of Ontario that expressed an interest in the full intervention (the regions, or hubs, contain a wide variety of nursing home types within a reasonable travel distance [i.e., <100 km])
- Nursing homes within the hubs in which the medical and administrative leads agree to and support the project
Key exclusion criteria (3 listed)
- Nursing homes with a previous or ongoing involvement in externally supported quality improvement initiatives focusing on antipsychotic medications
- Nursing homes without any prescribers caring for at least 10 residents routinely
- Nursing homes with fewer than 30 residents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Audit + FeedbackOnline Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care) | Behavioural | Audit + Feedback, Audit + Feedback + Educational Outreach |
| Audit + Feedback + Educational OutreachThe Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: "an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia." The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home. | Behavioural | Audit + Feedback + Educational Outreach |
Primary outcome
Antipsychotic dispensing
Time frame: 6 months post-intervention
Number of days with antipsychotic prescriptions in the last week (count, range 0 - 7)
12 secondary outcomes
Antipsychotic prescribing
Time frame: 3 and 6 months post-intervention
Mean Antipsychotic dose
Time frame: 3 and 6 months post-intervention
Benzodiazepine (or sedative) prescribing
Time frame: 3 and 6 months post-intervention
Anti-depressant prescribing
Time frame: 3 and 6 months post-intervention
Acetaminophen prescribing
Time frame: 3 and 6 months post-intervention
Difficulty in performing activities
Time frame: 3 and 6 months post-intervention
Aggressive behaviour scale
Time frame: 3 and 6 months post-intervention
Pain
Time frame: 3 and 6 months post-intervention
Depression
Time frame: 3 and 6 months post-intervention
Falls
Time frame: 3 and 6 months post-intervention
Emergency Room visits
Time frame: 3 months post-intervention
Hospitalizations
Time frame: 3 months post-intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2018.
- Derived from this study: PubMed 32453383Tadrous M, Fung K, Desveaux L, Gomes T, Taljaard M, Grimshaw JM, Bell CM, Ivers NM. Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2020 May 1;3(5):e205724. doi: 10.1001/jamanetworkopen.2020.5724.
- Derived from this study: PubMed 28549480Desveaux L, Saragosa M, Rogers J, Bevan L, Loshak H, Moser A, Feldman S, Regier L, Jeffs L, Ivers NM. Improving the appropriateness of antipsychotic prescribing in nursing homes: a mixed-methods process evaluation of an academic detailing intervention. Implement Sci. 2017 May 26;12(1):71. doi: 10.1186/s13012-017-0602-z.
- Derived from this study: PubMed 27026584Desveaux L, Gomes T, Tadrous M, Jeffs L, Taljaard M, Rogers J, Bell CM, Ivers NM. Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. Implement Sci. 2016 Mar 29;11:45. doi: 10.1186/s13012-016-0410-x.
- Individual participant dataSharing planned: No
Related trials for Adverse Effect of Other Antipsychotics and Neuroleptics
Recruiting
Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects
Treatment Resistant Schizophrenia, Obesity & Overweight
Not yet recruitingPhase 4
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Recruiting
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
Severe Mental Disorder, Metabolic Complication
Recruiting
Sex, Psychopharmacology, and Diabetes
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Noah Ivers principal investigator
Family Doctor and Research Scientist
Questions about this trial
What is this clinical trial studying?
A study testing Audit + Feedback and Audit + Feedback + Educational Outreach in people with Adverse Effect of Other Antipsychotics and Neuroleptics, run by Women's College Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antipsychotic dispensing (time frame: 6 months post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02604056, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2018.